CNS Pharmaceuticals, Inc.CNSP
Price (close)
$4.93
Market cap
$7.2M
P/E
—
Revenue (TTM)
—
Net income
-$16.7M
Dividend yield
—
1-year total return
-43.0%
Net margin
—
Revenue growth
—
Debt / equity
—
What CNS Pharmaceuticals, Inc. does.
diseases in neurology and oncology. Together, these therapeutic areas represent hundreds of billions of dollars in annual global pharmaceutical
spending, encompass some of the most prevalent and difficult to treat diseases affecting humanity, and are characterized by significant
unmet medical need. Significant progress has been made in the biological and molecular understanding of these diseases, enabling a shift
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$9.5M | -$14.5M | -$15.3M | -$18.9M | -$14.9M | -$15.9M |
| Free cash flow | -$7.3M | -$13.5M | -$10.6M | -$14.1M | -$17.1M | -$13.8M |
More on CNSP.
- CNS Pharmaceuticals, Inc. summary
- CNS Pharmaceuticals, Inc. financial statements
- CNS Pharmaceuticals, Inc. key metrics
- CNS Pharmaceuticals, Inc. health scores and style box
- CNS Pharmaceuticals, Inc. earnings
- CNS Pharmaceuticals, Inc. dividends
- CNS Pharmaceuticals, Inc. valuation
- CNS Pharmaceuticals, Inc. ownership and insiders
- CNS Pharmaceuticals, Inc. peers
Figures from CNS Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.